Novartis is navigating Entresto generic pressure with strong growth from Kisqali, Pluvicto, Leqvio, and Kesimpta. The stock looks durable, but valuation and near-term earnings pressure keep the stance at Hold.
Investment thesis: Novartis AG ADR (NVS) is a high-quality global pharmaceutical company moving through a difficult transition rather than a broken growth story. Q2 2026 net sales rose 1% in constant currencies to $14.4B, while core operating income held at $5.9B. That resilience came as Kisqali, Kesimpta, Scemblix, Pluvicto, and Leqvio offset substantial generic erosion, including the loss of Entresto exclusivity in the United States.
The investment case rests on a broad group of commercial growth drivers. In Q2, Kisqali grew 43% in constant currencies, Kesimpta 32%, Pluvicto 43%, Leqvio 59%, and Scemblix 89%. Novartis also reported more than 4,000 Rhapsido prescribers and more than 10,000 treated patients, while the pipeline advanced through six-year Kisqali survival data, an FDA filing for del-zota in Duchenne muscular dystrophy, and progress in ianalumab and remibrutinib.
The counterweight is valuation and near-term earnings pressure. NVS trades at 23.3x trailing earnings, 17.3x forward earnings, and 3.5x PEG, while full-year 2026 guidance calls for low-single-digit sales growth and a low-single-digit decline in core operating income. The late-August quote of $153.81 sits above the 200-day moving average of $149.12 and below the 52-week high of $165.43. This is a durable business at a demanding, but not extreme, price. The medium-term stance is Hold.
Novartis AG (NVS) is headquartered in Basel, Switzerland, and its ADR trades on the New York Stock Exchange. The company researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines across international markets. It employed 75,267 people, and Vasant Narasimhan serves as chief executive officer.
The modern NVS portfolio centers on four therapeutic areas: cardiovascular, renal and metabolic medicine; immunology; neuroscience; and oncology. Its principal technology platforms are gene and cell therapy, radioligand therapy, and xRNA, supported by chemistry and biotherapeutics. This structure gives NVS exposure to both established specialty medicines and newer treatment formats.
The company generated $54.81B of revenue in 2025, compared with $43.97B in 2021. The 2025 portfolio included Entresto at $7.75B, Cosentyx at $6.67B, Kisqali at $4.78B, Kesimpta at $4.43B, Pluvicto at $1.99B, Xolair at $1.72B, Scemblix at $1.29B, Leqvio at $1.20B, and Fabhalta at $505M. The numbers show a large commercial base, but also explain why patent expiry in one major product matters.
Oncology is the largest therapeutic area, with 2025 sales of $16.83B. Kisqali, Pluvicto, Scemblix, Fabhalta, Tafinlar plus Mekinist, Jakavi, Promacta plus Revolade, and Tasigna form the core of this business. The mix is improving because fast-growing products are taking a larger strategic role, although older oncology brands remain exposed to generic competition.
Immunology produced $10.29B in 2025, led by Cosentyx and Ilaris. Cosentyx grew 10% in constant currencies in Q2 2026, with US sales up 16%, while NVS reported additional competitive pressure in China. The franchise still benefits from new indications, including the REPLENISH-PMR study, where sustained remission at 52 weeks was twice as high with Cosentyx as with placebo.
Cardiovascular, renal and metabolic sales reached $8.96B in 2025. Entresto remains the major contributor, while Leqvio and Fabhalta provide the growth layer. Leqvio grew 59% in Q2, and Fabhalta received traditional FDA approval in July 2026 for primary IgA nephropathy. Neuroscience generated $5.99B in 2025, driven by Kesimpta and supported by Zolgensma and other assets.
The segment pattern is clear: mature products fund a pipeline of specialty launches, while the newer products must grow rapidly enough to replace patent-related losses. In Q2, management said the growth drivers were up 36% in constant currencies, illustrating the speed required to keep the whole company moving forward.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Entresto remains NVS's flagship commercial product by revenue, with 2025 sales of $7.75B. It treats symptomatic chronic heart failure with reduced ejection fraction and built a major cardiovascular franchise. Its strength also creates the largest near-term earnings challenge because US generic erosion affected the first half of 2026.
Management said the company is moving beyond the Entresto patent expiry and highlighted approximately $800M of US Entresto sales in the prior-year third-quarter comparison base. That creates a difficult transition for reported growth, even as the newer portfolio expands. Full-year 2026 guidance of low-single-digit sales growth reflects this bridge.
Kisqali is the most important growth flagship. Q2 sales increased 43% in constant currencies, US sales rose 39% to more than $1B, and the product reached 76 countries with reimbursement in 42. NVS remains confident in a $10B peak-sales goal. Six-year early breast cancer data also showed clinically meaningful overall survival, giving Kisqali a stronger foundation in earlier treatment settings.
Pluvicto adds a second high-value growth engine. Q2 sales rose 43%, more than 880 US sites were providing the therapy, and more than 650 sites outside the US were providing radioligand therapy. The July 2026 FDA approval in PSMA-positive metastatic hormone-sensitive prostate cancer expanded the eligible patient pool by 75%, according to the forecast context. That label expansion is a tangible commercial lever rather than a speculative pipeline promise.
NVS's competitive advantage comes from combining global scale with a concentrated specialty-medicine portfolio. Kisqali's six-year survival follow-up, Pluvicto's radioligand platform, Leqvio's twice-yearly administration, and Kesimpta's established multiple-sclerosis position each address a different commercial and clinical need.
That statement from CEO Vas Narasimhan captures the strategic shift. NVS is replacing dependence on mature blockbusters with several growing products rather than relying on one rescue asset. Scemblix grew 89% in constant currencies in Q2 and held 75% new-patient share in third-line and later treatment across key markets outside the US. Kesimpta also has a large conversion opportunity because two-thirds of international patients remain on older therapies rather than B-cell therapies.
The pipeline adds optionality. Rhapsido is expanding into chronic inducible urticaria, ianalumab is advancing across Sjogren's disease, immune thrombocytopenia, lupus, and systemic sclerosis, and remibrutinib has Phase III multiple-sclerosis data supporting global submissions. Del-zota's FDA accelerated-approval submission in Duchenne muscular dystrophy and del-brax biomarker data in facioscapulohumeral muscular dystrophy extend NVS's reach into genetic disease.
The moat is not permanent. NVS's 2025 annual report identifies patent loss, generic and biosimilar competition, pricing pressure, and clinical failure as major risks. The advantage is the scale to commercialize successful discoveries, not immunity from the industry's recurring patent cycle.
NVS manufactures and distributes medicines across Switzerland and international markets. Its operating model combines internal research and development, global regulatory capabilities, specialty sales infrastructure, and a network of treatment sites. Pluvicto's more than 880 US sites and more than 650 international radioligand sites illustrate the operational work required to commercialize complex therapies.
Q2 2026 also showed how inventory timing can distort the quarterly picture. Management said inventory-related changes added roughly one percentage point to sales in Q2 and would shift into Q3. Clinical-trial costs also moved from Q2 into Q3, producing an approximately five-percentage-point benefit to Q2 core operating income. This is a timing issue, not a permanent margin improvement.
Productivity remains an important operating tool. Q2 core operating margin was 41.2%, down 70 basis points from the prior year because of incremental Avidity costs and lower gross margin, with productivity gains providing an offset. Capital spending was $1.56B in 2025, while operating cash flow reached $19.24B, giving the company room to fund manufacturing, trials, and business development.
The main operational risk is complexity. Radioligand therapy requires specialized capacity and referral networks, while gene and cell therapy demands strict manufacturing and logistics controls. NVS's site expansion for Pluvicto reduces one bottleneck, but execution remains central to converting regulatory approvals into sales.
The global pharmaceutical market provides a large backdrop for NVS. Mordor Intelligence estimated the market at $1.74T in 2025 and projected $2.48T by 2031, implying a 6.0% compound annual growth rate. Grand View Research gave a similar 2025 estimate of $1.74T and projected $2.78T by 2033.
Growth is concentrated in specialty drugs, biologics, rare disease, targeted oncology, radioligand therapy, and advanced immune treatments. NVS is positioned directly in those areas through Kisqali, Pluvicto, Fabhalta, Scemblix, Rhapsido, Kesimpta, and its gene and cell therapy platform.
The market's attractive growth rate does not guarantee shareholder returns. Generics and biosimilars expand access while reducing branded revenue after exclusivity ends. NVS's 2025 results showed both forces at work: Kisqali, Pluvicto, Scemblix, and Fabhalta grew strongly, while Tasigna sales fell 34% and Promacta plus Revolade sales fell 26% because of generic competition.
The strategic prize is earlier-line adoption and broader labels. Kisqali's early breast cancer positioning, Pluvicto's expansion into hormone-sensitive disease, Fabhalta's renal indication, and Leqvio's growth in Medicare Part B all show NVS moving beyond narrow rescue markets.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
NVS sells through a multi-party healthcare system. Patients receive the therapies, physicians prescribe them, hospitals and specialty sites administer them, and insurers, pharmacy benefit managers, Medicare, and national health systems influence access and reimbursement. The commercial model therefore depends on clinical outcomes, treatment convenience, physician adoption, and payer economics.
The Q2 data show strong customer adoption in several franchises. Kisqali's total prescriber base increased 16%, and 58% of new patients in the early breast cancer population came from the N0 and N1 nodal groups highlighted by management. Rhapsido had more than 4,000 US prescribers and more than 10,000 treated patients, with 60% treated in the first-line setting.
Payer access is equally important. Two of the three major US pharmacy benefit managers covered Rhapsido with prior authorization tied to its label. Leqvio held 23.3% share in the Medicare Part B segment, up 3.6 percentage points year to date. Outside the US, Leqvio's inclusion on China's National Reimbursement Drug List doubled its market share compared with the pre-inclusion level.
These figures favor products with durable clinical differentiation or convenient dosing. Leqvio's persistence data and Kesimpta's move toward a possible every-two-month maintenance schedule address adherence and convenience, while Pluvicto's site expansion addresses access.
NVS competes with Roche (RHHBY), AstraZeneca (AZN), Pfizer (PFE), Merck & Co. (MRK), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly (LLY), Sanofi (SNY), and Amgen (AMGN). The correct benchmark is franchise by franchise because NVS spans oncology, immunology, neuroscience, and cardiovascular, renal and metabolic medicine.
In oncology, Kisqali competes in the CDK4/6 market, where NVS said it outpaced the market in Q2 and maintained metastatic breast cancer leadership. Pluvicto competes in targeted prostate cancer treatment, while Scemblix competes in chronic myeloid leukemia. Scemblix's 75% new-patient share in third-line and later treatment across key international markets is a specific sign of commercial strength.
In immunology, Cosentyx faces competition from AbbVie (ABBV), Johnson & Johnson (JNJ), Amgen (AMGN), Sanofi (SNY), and Roche (RHHBY). NVS reported additional competition in China but maintained global performance. In neuroscience, Kesimpta competes with therapies from Biogen (BIIB), Roche (RHHBY), Sanofi (SNY), and other specialty developers.
NVS's advantage is breadth combined with launch execution. Its Q2 product growth was spread across five major brands, not concentrated in one molecule. Its disadvantage is that large-cap pharma competitors possess similar regulatory scale, deep balance sheets, and established payer relationships.
US pricing policy is the most important external pressure. Entresto was selected for a US maximum fair price for 2026, while Cosentyx, Kisqali, and Xolair were selected for the Medicare Drug Price Negotiation Program for 2028. These actions create long-term pricing risk for products that otherwise have strong commercial momentum.
NVS also reported a December 19, 2025 agreement with the US government aimed at lowering innovative-medicine prices while supporting US manufacturing and research investment. The policy direction favors companies with differentiated products and strong productivity, but it can reduce the revenue captured per treated patient.
Geographic exposure creates both opportunity and friction. Leqvio benefited from National Reimbursement Drug List inclusion in China, while Cosentyx faced more competition there. NVS is also expanding in Japan and Europe through Pluvicto, Scemblix, Kisqali, and Rhapsido. Foreign exchange adds another variable: management estimated that mid-July exchange rates would provide a one-percentage-point benefit to both full-year sales and core operating income.
The macro profile is defensive in demand but exposed to policy. Patients require treatment through economic cycles, yet governments and payers have direct influence over reimbursement. That combination supports revenue resilience while limiting the pricing power implied by a premium growth narrative.
A B- balance sheet grade reflects a large global pharma cash engine, but the report flags enough transition risk that leverage and capital allocation still matter.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 net sales rose just 1% in constant currencies to $14.4B even as core operating income held at $5.9B, showing resilience amid Entresto erosion.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Full-year 2026 guidance calls for low-single-digit sales growth and a low-single-digit decline in core operating income, so the next leg depends on newer launches scaling fast.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At 23.3x trailing earnings, 17.3x forward earnings, and a 3.5x PEG, NVS is priced for quality rather than a bargain.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →With the quote at $153.81 versus fair value of $155, the report sees limited near-term upside and keeps the medium-term stance at Hold.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Novartis AG ADR (NVS) has the profile of a strong pharmaceutical compound: high margins, substantial cash generation, global reach, and several active growth engines. Q2 2026 showed the model working under pressure, with 1% constant-currency sales growth despite generic erosion and flat core operating income.
The medium-term case depends on execution after Entresto. Kisqali's $10B peak-sales goal, Pluvicto's 75% larger eligible patient pool, Scemblix's early-line expansion, Leqvio's payer traction, Kesimpta's international opportunity, and the Rhapsido and ianalumab launches provide several routes to renewed growth. The 2027 to 2030 estimates give that strategy financial shape.
The stock does not offer a large discount at $153.81. Its 23.3x trailing P/E, 17.3x forward P/E, 3.5 PEG ratio, higher debt, and pricing exposure limit the upside from multiple expansion. A Hold is therefore the disciplined position at present, while a decline toward $140.00 would improve the entry case for a moderate-risk, medium-term investor.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Novartis AG (NVS) falls sharply after two late-stage trial failures hit investor confidence. The selloff reflects lost pipeline value, especially for pelacarsen, even as the company’s core business remains profitable and growing.
Novartis AG (NVS) rises after reporting positive Phase III data for remibrutinib in relapsing multiple sclerosis. The late-stage results boosted investor confidence in the company’s pipeline, even as traders weighed regulatory risk, competition in MS, and a separate clinical setback in another program.
Casey's General Stores, Inc. (CASY) falls in extended-hours trading even after posting a strong Q1 FY2027 earnings beat. Investors focused on mixed operating trends, including softer fuel volumes and a premium valuation, prompting a sharp pullback despite better-than-expected EPS and revenue.